Seres Therapeutics Investor Presentation May 2025 Disclaimers 2 Seres Therapeutics, Inc. © 2025 2 Transforming patient outcomes using proprietary consortia of live biotherapeutics Strong Foundation Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including s ...

The Company plans to submit a Phase 2 trial protocol for SER-155 in allo-HSCT to the FDA in the coming weeks and is actively seeking partners to support continued clinical development. Presentation Details Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or th ...

Core Viewpoint - Seres Therapeutics (MCRB) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Recent Performance of Seres Therapeutics - Seres Therapeutics is projected to earn -$1.67 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 89.7% [8]. - Over the past three months, the Zacks Consensus Estimate for Seres Therapeutics has increased by 85%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Seres Therapeutics to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Seres Therapeutics (MCRB) shows significant upside potential with a mean price target of $60.25, indicating a 713.1% increase from its current price of $7.41 [1] Price Targets and Analyst Consensus - The average price target for MCRB ranges from a low of $6 to a high of $200, with a standard deviation of $93.35, indicating high variability among analysts [2] - The lowest estimate suggests a 19% decline from the current price, while the highest estimate indicates a potential upside of 2599.1% [2] - A tight clustering of price targets, represented by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising MCRB's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 80.3%, with three estimates moving higher and no negative revisions [12] - MCRB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

Financial Data and Key Metrics Changes - Seres Therapeutics reported a net income from continuing operations of $32.7 million in Q1 2025, compared to a net loss of $32.9 million in Q1 2024, primarily driven by a $50 million installment payment received from Nestle [14] - Research and development expenses decreased to $11.8 million from $19.5 million in Q1 2024, reflecting lower personnel expenses and reduced costs related to the SER-155 Phase Ib study [15] - General and administrative expenses were $11.9 million in Q1 2025, down from $14.9 million in Q1 2024, mainly due to lower personnel and contractor expenses [15] - As of March 31, 2025, the company had cash and cash equivalents of $58.8 million, with an expected second installment payment of approximately $23.5 million from Nestle in July 2025 [15][16] Business Line Data and Key Metrics Changes - The company is advancing SER-155 into the next stage of development in allo HSCT, with a Phase 1b study showing a 77% relative risk reduction in bloodstream infections compared to placebo [6][7] - SER-155 is positioned to redefine the standard of care for allo HSCT recipients and other vulnerable patient groups at risk of bloodstream infections, indicating significant commercial opportunities [7][12] Market Data and Key Metrics Changes - Feedback from healthcare providers at the European Society for Blood and Marrow Transplantation Conference highlighted the ongoing clinical challenge of preventing bloodstream infections, with enthusiasm for SER-155's safety and efficacy results [8] - The company received external validation for SER-155, as its poster won the best clinical poster award at the conference, reinforcing the patient need and scientific rigor [9] Company Strategy and Development Direction - The company aims to submit a Phase II study protocol to the FDA in the coming weeks, incorporating constructive feedback received from the agency [10][18] - Seres Therapeutics is exploring partnerships to secure financial support for advancing SER-155, recognizing the challenging biotech financing environment [12][16] - The strategic focus includes not only allo HSCT but also addressing gut-related inflammatory and immune diseases such as IBD, indicating a broader therapeutic potential for live biotherapeutics [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made with SER-155, citing encouraging clinical data and constructive regulatory feedback [18] - The company is prioritizing activities that advance clinical and strategic goals while exploring additional capital sources to support the Phase II study [16] Other Important Information - A one-for-20 reverse stock split was executed on April 21, 2025, with trading on a split-adjusted basis commencing on April 22, 2025, leading to regained compliance with NASDAQ listing requirements [16] Q&A Session Summary Question: Are partnership discussions gated by progress around SER-155? - Management indicated that securing a partnership is a key long lead time item for moving forward with the study, while they are advancing other necessary preparations [23][24] Question: Can you outline the powering assumptions for the Phase II study? - Management stated that the Phase II study is designed to allow data to be used for both efficacy and safety components for submission to the FDA, with an interim analysis planned [25][26][28] Question: Any updates on FDA interactions and partnership discussions? - Management reported constructive and regular interactions with the FDA, which have been helpful in moving forward, and they are making progress in partnership discussions [33][36][38] Question: Will the Phase II study include overall survival as an endpoint? - The primary endpoint for the Phase II study is bloodstream infection reductions, with discussions ongoing regarding potential efficacy measures for a Phase III study [46][49]

Seres Therapeutics (MCRB) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Seres Therapeutics First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference o ...

Exhibit 99.1 SERES THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended me ...

Recent Highlights In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction ...

Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New results presented at the DDW conference could help identify candidate biomarkers to support the further clinical devel ...